Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celularity IncCELU · Entity 7145 | Chief Medical Officer | February 16, 2024 | February 22, 2024 |
| HUMANIGEN, INCHGEN · Entity 108862 | Chief Medical Officer | July 27, 2022 | July 29, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celularity Inc
Report date February 16, 2024 · Filed February 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,122,238 |
Reported balance
After 2024-02-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-17 · Tax withholding · Disposed 52,762 · Balance 1,122,238 F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale. F2: Reflects shares underlying RSUs subject to vesting. |
| Stock Option Grant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2034-02-15 | Direct | 205,213 |
Reported balance
After 2024-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-16 · Grant · Acquired 205,213 · Balance 205,213 F3: The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale.
F2: Reflects shares underlying RSUs subject to vesting.
F3: The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date.
HUMANIGEN, INC
Report date July 27, 2022 · Filed July 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2032-07-26 | Direct | 537,164 |
Reported balance
After 2022-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-27 · Grant · Acquired 537,164 · Balance 537,164 F1: The stock option vests in two equal installments on the first and second anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in two equal installments on the first and second anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2024 Filed Feb 22, 2024 02:38 UTC | Celularity Inc CELU · Entity 7145 | Tax withholdingClass A Common Stock | 52,762 | $0.43 | $22,898.71 |
DisclosureSEC source: 0001493152-24-007487 · ownership.xml · nonDerivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,122,238 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale. F2 · balance_after: Reflects shares underlying RSUs subject to vesting. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:38 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option Grant (Right to Buy) · Derivative | 205,213 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001493152-24-007487 · ownership.xml · derivative · entry 2 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,213 Underlying: Class A Common Stock · 205,213 shares Expires 2034-02-15 F3 · derivative.exercise_date: The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| July 14, 2023 Filed Jul 19, 2023 16:21 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 875,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-033475 · ownership.xml · nonDerivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,175,000 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs are subject to (i) time-based vesting over a three-year period, with 25% vesting on the one-year anniversary of the grant date, 25% vesting on the two-year anniversary of the grant date, and the remainder vesting on the three-year anniversary of the grant date, and (ii) performance-based vesting based on the Issuer's stock price, and in each case subject to the Reporting Person's continuous service on each vesting date. F2 · balance_after: Reflects shares underlying RSUs subject to vesting. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 02:18 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-005916 · doc4.xml · nonDerivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F1 · price: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs is subject to time-based vesting over a two-year period, with 50% vesting on the one-year anniversary of the grant date, and the remainder vesting on the two-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 20:10 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 66,226 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0000899243-22-032650 · doc4.xml · derivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,226 Underlying: Class A Common Stock · 66,226 shares Expires 2032-10-03 F1 · derivative.exercise_date: This option was granted under the Issuer's 2021 Equity Incentive Plan. The shares underlying such option vest and become exercisable as follows: 25% on the one-year anniversary of the grant date, with the remainder vesting monthly thereafter so that it will be vested in full on the four-year anniversary of the grant date, subject to the Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 18:31 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 537,164 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001214659-22-009391 · marketforms-56759.xml · derivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,164 Underlying: Common Stock · 537,164 shares Expires 2032-07-26 F1 · derivative.exercise_date: The stock option vests in two equal installments on the first and second anniversaries of the grant date. Read SEC document |
| March 09, 2022 Filed Mar 14, 2022 16:37 UTC | HUMANIGEN, INC HGEN · Entity 108862 | PurchaseCommon Stock | 5,000 | $2.78 | $13,900.00 |
DisclosureSEC source: 0001214659-22-003919 · marketforms-55788.xml · nonDerivative · entry 2 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.75 to $2.80, inclusive. The reporting person undertakes to provide upon request to the issuer, the Securities and Exchange Commission or any security holder of the issuer full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 08, 2022 Filed Mar 14, 2022 16:37 UTC | HUMANIGEN, INC HGEN · Entity 108862 | PurchaseCommon Stock | 7,000 | $2.53 | $17,710.00 |
DisclosureSEC source: 0001214659-22-003919 · marketforms-55788.xml · nonDerivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.52 to $2.53, inclusive. The reporting person undertakes to provide upon request to the issuer, the Securities and Exchange Commission or any security holder of the issuer full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 17:05 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 38,411 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001214659-22-000733 · marketforms-55062.xml · derivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,411 Underlying: Common Stock · 38,411 shares Expires 2032-01-11 F1 · price: The stock option was granted to the Reporting Person at the direction of the Company in satisfaction of amounts earned under the Company's 2021 annual incentive plan. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 18:20 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 34,500 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001214659-22-000266 · marketforms-54936.xml · derivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 34,500 shares Expires 2031-12-30 F1 · derivative.exercise_date: The option vests in 12 ratable quarterly installments commencing March 31, 2022. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 17:15 UTC | HUMANIGEN, INC HGEN · Entity 108862 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,863 | $4.53 Strike: $5.93 | $26,559.39 |
DisclosureSEC source: 0001214659-21-012330 · marketforms-54402.xml · derivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,863 shares Expires 2031-09-30 F1 · shares: As reported in a Form 8-K filed by Humanigen, Inc. (the "Company") on November 26, 2021, with the approval of the compensation committee of the board of directors of the Company, the reporting person accepted the Company's offer to rescind his participation in the program pursuant to which the reporting person had agreed to receive stock options in lieu of 25% of his base salary for the fourth quarter of 2021, or $26,546. As a result, the stock option granted to the reporting person on September 30, 2021 was cancelled, and the reporting person will receive 100% of his base salary for the fourth quarter of 2021 in cash. The amount shown in column 8 equals the fair value of the option on the grant date of September 30, 2021 as calculated using the Black-Scholes options pricing model. F1 · price: As reported in a Form 8-K filed by Humanigen, Inc. (the "Company") on November 26, 2021, with the approval of the compensation committee of the board of directors of the Company, the reporting person accepted the Company's offer to rescind his participation in the program pursuant to which the reporting person had agreed to receive stock options in lieu of 25% of his base salary for the fourth quarter of 2021, or $26,546. As a result, the stock option granted to the reporting person on September 30, 2021 was cancelled, and the reporting person will receive 100% of his base salary for the fourth quarter of 2021 in cash. The amount shown in column 8 equals the fair value of the option on the grant date of September 30, 2021 as calculated using the Black-Scholes options pricing model. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:05 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 5,863 | $0.00 Strike: $5.93 | $0.00 |
DisclosureSEC source: 0001214659-21-010213 · marketforms-53962.xml · derivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,863 Underlying: Common Stock · 5,863 shares Expires 2031-09-30 F1 · derivative.exercise_date: This stock option was granted to the reporting person in lieu of 25% of his base salary for the fourth quarter of 2021. The option vests in three ratable installments on each of October 31, 2021, November 30, 2021 and December 31, 2021. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 16:44 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $14.99 | $0.00 |
DisclosureSEC source: 0001214659-21-004393 · marketforms-52317.xml · derivative · entry 1 Kilcoyne Adrian · CIK 0001857963 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2031-04-20 F1 · derivative.exercise_date: The option vests in 12 ratable quarterly installments commencing September 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.